Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022

Björk, Jonas LU ; Bonander, Carl ; Moghaddassi, Mahnaz LU ; Rasmussen, Magnus LU ; Malmqvist, Ulf LU ; Inghammar, Malin LU and Kahn, Fredrik LU (2022) In Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 27(18).
Abstract

We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.

Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
epidemiological surveillance, SARS-CoV-2 vaccine effectiveness, variant of concern
in
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
volume
27
issue
18
publisher
European Centre for Disease Prevention and Control (ECDC)
external identifiers
  • scopus:85129356434
  • pmid:35514304
ISSN
1560-7917
DOI
10.2807/1560-7917.ES.2022.27.18.2200322
project
Improved preparedness for future pandemics and other health crises through large-scale disease surveillance
language
English
LU publication?
yes
id
be0b6d9a-7931-42de-9435-5f0889f9cd8b
date added to LUP
2022-07-06 15:24:31
date last changed
2024-06-27 11:17:06
@article{be0b6d9a-7931-42de-9435-5f0889f9cd8b,
  abstract     = {{<p>We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.</p>}},
  author       = {{Björk, Jonas and Bonander, Carl and Moghaddassi, Mahnaz and Rasmussen, Magnus and Malmqvist, Ulf and Inghammar, Malin and Kahn, Fredrik}},
  issn         = {{1560-7917}},
  keywords     = {{epidemiological surveillance; SARS-CoV-2 vaccine effectiveness; variant of concern}},
  language     = {{eng}},
  number       = {{18}},
  publisher    = {{European Centre for Disease Prevention and Control (ECDC)}},
  series       = {{Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin}},
  title        = {{COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022}},
  url          = {{http://dx.doi.org/10.2807/1560-7917.ES.2022.27.18.2200322}},
  doi          = {{10.2807/1560-7917.ES.2022.27.18.2200322}},
  volume       = {{27}},
  year         = {{2022}},
}